 STAMFORD, Conn. and ST. GALLEN, Switzerland, Aug. 23, 2021 GLOBE NEWSWIRE -- Cara Therapeutics Nasdaq: CARA and Vifor Pharma today announced that the U.S. Food and Drug Administration FDA has approved KORSUVATM difelikefalin for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis . KORSUVATM injection is a first-in-class kappa opioid receptor KOR agonist that targets the bodys peripheral nervous system. The KORSUVATM injection new drug application NDA received Priority Review by the FDA, which is granted to therapies that, if approved, would offer significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications. 